Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Open in Screener

NTRA

Natera Inc

Nov 21 • 04:00PM ET

230.63

+5.08 2.25 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN GH TXG EXAS QGEN FLGT TWST MYGN CDNA BNGO

| Held by: VTI VB VBK VXF IBB IWP XBI IWF IWR ARKK

Index	-	P/E	-	EPS (ttm)	-2.28	Insider Own	5.03%	Shs Outstand	137.53M	Perf Week	12.90%
Market Cap	31.83B	Forward P/E	-	EPS next Y	-1.78	Insider Trans	-7.28%	Shs Float	131.07M	Perf Month	18.27%
Enterprise Value	30.99B	PEG	-	EPS next Q	-0.50	Inst Own	94.16%	Short Float	2.98%	Perf Quarter	41.95%
Income	-309.19M	P/S	15.04	EPS this Y	-55.96%	Inst Trans	-1.04%	Short Ratio	3.16	Perf Half Y	50.42%
Sales	2.12B	P/B	25.33	EPS next Y	25.52%	ROA	-18.12%	Short Interest	3.91M	Perf YTD	45.69%
Book/sh	9.10	P/C	30.53	EPS next 5Y	57.12%	ROE	-29.02%	52W High	229.95 0.30%	Perf Year	42.28%
Cash/sh	7.55	P/FCF	300.12	EPS past 3/5Y	33.57% 3.18%	ROIC	-22.79%	52W Low	125.38 83.94%	Perf 3Y	527.91%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.47% 41.20%	Gross Margin	63.66%	Volatility	4.44% 4.18%	Perf 5Y	181.81%
Dividend TTM	-	EV/Sales	14.64	EPS Y/Y TTM	-28.77%	Oper. Margin	-16.62%	ATR (14)	8.41	Perf 10Y	2213.24%
Dividend Ex-Date	-	Quick Ratio	3.13	Sales Y/Y TTM	38.17%	Profit Margin	-14.61%	RSI (14)	79.40	Recom	1.36
Dividend Gr. 3/5Y	- -	Current Ratio	3.27	EPS Q/Q	-150.04%	SMA20	13.01%	Beta	1.55	Target Price	235.20
Payout	-	Debt/Eq	0.16	Sales Q/Q	34.66%	SMA50	23.81%	Rel Volume	2.32	Prev Close	225.55
Employees	4434	LT Debt/Eq	0.08	Earnings	Nov 06 AMC	SMA200	41.48%	Avg Volume	1.24M	Price	230.63
IPO	Jul 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-65.93% 15.33%	Trades		Volume	2,869,898	Change	2.25%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-27-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$172
Sep-22-25	Resumed	Wells Fargo	Equal Weight	$175
Mar-13-25	Initiated	RBC Capital Mkts	Outperform	$251
Jan-23-25	Initiated	Barclays	Overweight	$200
Jun-03-24	Resumed	Jefferies	Buy	$142
Apr-08-24	Resumed	Craig Hallum	Buy	$117
Feb-20-24	Downgrade	Raymond James	Strong Buy → Outperform	$68 → $85
Dec-29-23	Reiterated	BTIG Research	Buy	$75 → $85
Dec-14-23	Initiated	Guggenheim	Buy	$70
Dec-13-23	Initiated	Wolfe Research	Outperform	$70
Nov-13-23	Upgrade	Raymond James	Outperform → Strong Buy	$68
Sep-28-23	Initiated	Bernstein	Mkt Perform	$48
Jul-05-23	Resumed	JP Morgan	Overweight	$85
May-05-23	Initiated	UBS	Buy	$76
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$58
Aug-25-22	Initiated	Credit Suisse	Outperform	$70
Apr-25-22	Initiated	Stephens	Overweight	$54
Mar-08-22	Initiated	Goldman	Buy	$90
Jan-06-22	Resumed	Piper Sandler	Overweight	$110
Oct-15-21	Resumed	Cowen	Outperform	$150

Show Previous Ratings

Today 06:55PM	Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know (StockStory)
Nov-20-25 01:25PM	Cathie Wood Targets New Tech Winners, Dumps AMD in Major Shuffle (GuruFocus.com)
Nov-19-25 10:40PM	Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3 (StockStory)
08:00AM	Employees Volunteer Over 1,500 Hours During Natera's Annual Volunteer Month (Business Wire)
Nov-18-25 04:45AM	TD Cowen Lifts Natera (NTRA) Target to $240, Reiterates Buy Rating (Insider Monkey)
03:05PM	Loading…
Nov-14-25 03:05PM	Stanley Druckenmiller's Strategic Moves: Exiting Philip Morris International Inc with a -3. ... (GuruFocus.com)
07:58AM	Does Natera (NTRA) Have a Long Runway For Growth? (Insider Monkey)
Nov-12-25 08:00AM	Natera Integrates with Flatiron Health's OncoEMR Platform (Business Wire)
Nov-11-25 11:39PM	1 Healthcare Stock with Impressive Fundamentals and 2 Facing Headwinds (StockStory)
Nov-07-25 09:27AM	NTRA Q3 Deep Dive: Oncology Momentum and New Product Expansion Drive Guidance Increase (StockStory)
12:03AM	Natera Inc (NTRA) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions (GuruFocus.com)
Nov-06-25 07:30PM	Here's What Key Metrics Tell Us About Natera (NTRA) Q3 Earnings (Zacks)
05:50PM	Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:02PM	Natera (NASDAQ:NTRA) Delivers Impressive Q3 (StockStory)
04:46PM	Natera: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Natera Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-04-25 10:19PM	Natera (NTRA) Reports Earnings Tomorrow: What To Expect (StockStory)
Oct-31-25 07:00AM	Natera Announces Expansion to 20 Genes for its Fetal Focus Single-Gene NIPT (Business Wire)
Oct-30-25 07:00AM	Natera to Report its Third Quarter Results on November 6, 2025 (Business Wire)
Oct-28-25 07:00AM	Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity (Business Wire)
Oct-27-25 06:20AM	Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-20-25 11:31PM	Reflecting On Immuno-Oncology Stocks' Q2 Earnings: Natera (NASDAQ:NTRA) (StockStory)
01:35PM	Why Are Natera (NTRA) Shares Soaring Today (StockStory)
01:05AM	Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients (Business Wire)
Oct-16-25 08:00AM	Natera Named to Fast Company's Next Big Things in Tech List (Business Wire)
Oct-13-25 09:28AM	Natera Signatera Validation Study Published in JCO PO Shows Superior Prognostic Value in Testicular Cancer (Insider Monkey)
08:00AM	Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings (Business Wire)
Oct-12-25 06:10PM	Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium (Business Wire)
Oct-06-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Sep-30-25 08:00AM	Natera Announces Publication of Signatera Validation Study in Testicular Cancer (Business Wire)
08:00AM	Loading…
Sep-29-25 08:00AM	Signatera Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows (Business Wire)
12:36AM	2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds (StockStory)
Sep-24-25 04:05PM	Why Natera (NTRA) Stock Is Down Today (StockStory) -5.16%
Sep-23-25 01:13PM	Biotech Stocks Rally. 3 Favorite Plays From the Charts. (Barrons.com)
Sep-22-25 09:35AM	Humana initiated, Paycom upgraded: Wall Street's top analyst calls (The Fly)
Sep-12-25 04:01PM	Why Natera (NTRA) Stock Is Trading Lower Today (StockStory)
Sep-10-25 03:11PM	Why Natera (NTRA) Shares Are Falling Today (StockStory)
12:02AM	3 Reasons We're Fans of Natera (NTRA) (StockStory)
Sep-02-25 01:04AM	Natera (NTRA) Provides an Update on its Intellectual Property Litigation With NeoGenomics (Insider Monkey)
Aug-29-25 05:05PM	Health Care Roundup: Market Talk (The Wall Street Journal)
01:46PM	Why Natera (NTRA) Stock Is Down Today (StockStory)
01:04PM	NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims (Benzinga)
08:18AM	Natera Provides Update on Patent Litigation with NeoGenomics (Business Wire)
04:46AM	Nateras Signatera test to be used in Phase III bladder cancer trial (Medical Device Network)
Aug-28-25 03:56PM	Why Natera (NTRA) Stock Is Up Today (StockStory)
08:00AM	Signatera Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer (Business Wire)
Aug-25-25 12:52PM	Natera Shares Rise on the Launch of AI Platform for Precision Oncology (Zacks)
08:00AM	Natera to Present Signatera Data at the IASLC World Conference on Lung Cancer (Business Wire)
Aug-22-25 06:04AM	Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine (Business Wire)
05:00AM	Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation (Business Wire)
12:40AM	1 Healthcare Stock to Own for Decades and 2 We Find Risky (StockStory)
Aug-18-25 12:33PM	Natera pursues ctDNA assay approval after Phase III victory (Clinical Trials Arena)
06:00AM	IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera Strongly Predicting Adjuvant Immunotherapy Benefit (Business Wire)
Aug-15-25 07:15PM	Stanley Druckenmiller's Strategic Moves: Significant Reduction in Coupang Inc. by 3.73% (GuruFocus.com)
Aug-14-25 06:06PM	Liberty All-Star® Growth Fund, Inc. July 2025 Monthly Update (Business Wire)
01:41AM	5 Revealing Analyst Questions From Natera's Q2 Earnings Call (StockStory)
Aug-13-25 07:30AM	1 Strong Buy Stock Analysts Think Will Soar 62% (Barchart)
Aug-12-25 03:27AM	NTRA Q2 Deep Dive: Oncology Growth, Product Innovation, and Margin Pressures (StockStory)
Aug-08-25 12:21PM	Why Are Natera (NTRA) Shares Soaring Today (StockStory) +7.70%
06:21AM	Natera introduces prenatal test for detecting inherited conditions (Medical Device Network)
05:33AM	Natera (NASDAQ:NTRA) Delivers Strong Q2 Numbers, Stock Jumps 12.6% (StockStory)
Aug-07-25 07:00PM	Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics (Zacks)
06:15PM	Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:12PM	Natera: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Second Quarter 2025 Financial Results (Business Wire)
07:00AM	Natera Launches Fetal Focus: A Noninvasive Prenatal Test for Inherited Conditions (Business Wire)
Aug-05-25 11:04PM	What To Expect From Natera's (NTRA) Q2 Earnings (StockStory)
07:10AM	Pediatrix Medical Group (MD) Q2 Earnings and Revenues Top Estimates (Zacks)
Aug-01-25 07:00AM	Natera Highlights Latest Prospera Data at WTC 2025; 16 Abstracts Including Five Oral Presentations (Business Wire)
Jul-31-25 07:00AM	Natera to Report Its Second Quarter Results on August 7, 2025 (Business Wire) -5.18%
Jul-30-25 07:06AM	Natera initiates trial of Signatera test for breast cancer (Medical Device Network)
Jul-29-25 07:00AM	Natera Announces Launch of ABCSG 61 ("TEODOR"), a Randomized Controlled Trial of Signatera in Early-Stage Breast Cancer (Business Wire)
Jul-28-25 06:48AM	Non-Invasive Prenatal Testing Market Forecast and Company Analysis Report 2025-2033 Featuring Eurofins Scientific, F. Hoffmann-La Roche, Invitae, Illumina, Natera, Centogene, and Qiagen (GlobeNewswire)
Jul-25-25 11:28PM	RBC Capital Maintains a Buy on Natera (NTRA) With a $251 PT (Insider Monkey)
Jul-24-25 08:00AM	PEDAL Study Successful, Shows Monitoring with Prospera Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT (Business Wire)
Jul-21-25 05:25PM	Medpace (MEDP) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Jul-14-25 02:19PM	Liberty All-Star® Growth Fund, Inc. June 2025 Monthly Update (Business Wire)
01:39PM	Natera, Inc. (NTRA): A Bull Case Theory (Insider Monkey)
Jul-08-25 08:49AM	Natera CEO on cancer recurrence detection and how it works (CNBC TV)
Jul-07-25 07:00AM	Natera Presents Data at ESMO GI on its Tissue-Free Latitude MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer (Business Wire)
Jul-04-25 08:43AM	Tempus AI Revenues & Profit Rise: What to Expect Ahead of Q2 Release (Zacks)
07:53AM	Should You Invest in Natera (NTRA)? (Insider Monkey)
Jul-01-25 04:05PM	Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD (Business Wire)
Jun-29-25 11:33PM	Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA) (StockStory)
Jun-24-25 04:25AM	Natera Gains Medicare Coverage for WGS Signatera, Leerink Reaffirms Price Target (Insider Monkey)
Jun-22-25 08:00AM	If You Can Only Buy 1 Cathie Wood Stock in 2025, It Should Be This (Barchart)
Jun-20-25 12:04AM	3 Reasons We Love Natera (NTRA) (StockStory)
Jun-12-25 06:20AM	Should Vanguard Small-Cap Growth ETF (VBK) Be on Your Investing Radar? (Zacks)
Jun-10-25 06:30AM	NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase (StockStory)
Jun-04-25 07:00AM	Natera Announces Medicare Coverage for Signatera Genome (Business Wire)
Jun-02-25 04:05PM	SignateraTM Genome Clinical Performance Highlighted at ASCO 2025 (Business Wire)
May-27-25 06:20AM	Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? (Zacks)
May-22-25 05:08PM	Natera to Present over 25 Signatera Studies at 2025 ASCO Annual Meeting (Business Wire)
May-20-25 06:20AM	Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? (Zacks)
May-13-25 10:08AM	Natera, Inc. (NTRA): A Bull Case Theory (Insider Monkey)
May-09-25 07:45AM	Q1 2025 Natera Inc Earnings Call (Thomson Reuters StreetEvents) -6.53%
03:39AM	Natera Inc (NTRA) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Raised Guidance (GuruFocus.com)
May-08-25 08:30PM	Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:55PM	Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:54PM	Natera: Q1 Earnings Snapshot (Associated Press Finance)

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sheena Jonathan	CO-FOUNDER	Nov 20 '25	Sale	225.08	10,000	2,250,816	222,660	Nov 21 08:05 PM
Sheena Jonathan	CO-FOUNDER	Nov 21 '25	Sale	230.01	4,000	920,030	23,282	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 20 '25	Option Exercise	41.17	7,668	315,689	26,027	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 19 '25	Option Exercise	40.93	5,112	209,234	23,471	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 20 '25	Sale	223.08	7,668	1,710,600	18,359	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 19 '25	Sale	215.00	5,112	1,099,088	18,359	Nov 21 08:05 PM
ROY BAYNES	Director	Nov 20 '25	Proposed Sale	223.08	7,668	1,710,600		Nov 20 04:03 PM
Sheena Jonathan	Director	Nov 20 '25	Proposed Sale	225.02	10,000	2,250,186		Nov 20 11:21 AM
ROY BAYNES	Director	Nov 19 '25	Proposed Sale	215.00	5,112	1,099,088		Nov 19 04:04 PM
Sheena Jonathan	CO-FOUNDER	Nov 07 '25	Sale	192.56	3,070	591,159	232,660	Nov 12 08:35 PM
Sheena Jonathan	CO-FOUNDER	Nov 11 '25	Sale	207.96	1,500	311,934	25,282	Nov 12 08:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 04 '25	Sale	200.51	22,900	4,591,674	2,280,852	Nov 04 09:35 PM
Sheena Jonathan	CO-FOUNDER	Nov 03 '25	Sale	200.07	4,000	800,274	26,032	Nov 04 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Nov 03 '25	Sale	198.60	3,000	595,810	112,061	Nov 04 09:35 PM
Marcus Gail Boxer	Director	Nov 03 '25	Sale	198.71	122	24,243	5,762	Nov 04 09:05 PM
MATTHEW RABINOWITZ	Director	Nov 04 '25	Proposed Sale	198.23	22,900	4,539,467		Nov 04 04:33 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Nov 03 '25	Option Exercise	116.02	155,679	18,062,483	305,519	Nov 03 09:40 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Nov 03 '25	Sale	199.96	160,703	32,133,981	144,816	Nov 03 09:40 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 03 '25	Sale	200.00	17,100	3,420,003	2,303,752	Nov 03 09:35 PM
MATTHEW RABINOWITZ	Director	Nov 03 '25	Proposed Sale	198.93	17,100	3,401,703		Nov 03 04:26 PM
SOLOMON MOSHKEVICH	Officer	Nov 03 '25	Proposed Sale	198.60	3,000	595,810		Nov 03 04:07 PM
STEVEN L CHAPMAN	Officer	Nov 03 '25	Proposed Sale	199.96	160,703	32,133,983		Nov 03 04:03 PM
Gail Marcus	Director	Nov 03 '25	Proposed Sale	198.71	122	24,243		Nov 03 01:24 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 28 '25	Sale	191.46	3,680	704,580	149,840	Oct 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 27 '25	Sale	192.32	2,335	449,077	153,520	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 28 '25	Sale	191.16	2,415	461,648	65,993	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 29 '25	Sale	190.64	1,867	355,925	64,126	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 27 '25	Sale	192.32	781	150,205	68,408	Oct 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Oct 27 '25	Sale	192.32	288	55,389	235,921	Oct 29 09:05 PM
Sheena Jonathan	CO-FOUNDER	Oct 28 '25	Sale	191.46	191	36,569	235,730	Oct 29 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 28 '25	Sale	191.46	1,058	202,567	201,699	Oct 29 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 27 '25	Sale	192.32	935	179,823	202,757	Oct 29 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 28 '25	Sale	191.46	1,198	229,371	115,061	Oct 29 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 27 '25	Sale	192.32	1,008	193,863	116,259	Oct 29 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 28 '25	Sale	191.46	928	177,677	150,699	Oct 29 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 27 '25	Sale	192.32	781	150,205	151,627	Oct 29 09:05 PM
MICHAEL BROPHY	Officer	Oct 29 '25	Proposed Sale	189.57	1,867	353,927		Oct 29 04:23 PM
MICHAEL BROPHY	Officer	Oct 28 '25	Proposed Sale	192.22	1,178	226,435		Oct 28 04:16 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 22 '25	Sale	186.68	920	171,746	69,189	Oct 24 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 24 '25	Sale	196.77	755	148,561	69,189	Oct 24 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 23 '25	Sale	187.16	495	92,644	69,944	Oct 24 09:35 PM
MICHAEL BROPHY	Officer	Oct 24 '25	Proposed Sale	195.00	755	147,225		Oct 24 04:26 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Oct 20 '25	Sale	190.00	10,000	1,900,000	5,000	Oct 22 09:05 PM
Sheena Jonathan	CO-FOUNDER	Oct 21 '25	Sale	187.95	93	17,479	236,209	Oct 22 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 21 '25	Sale	187.95	464	87,209	203,692	Oct 22 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 21 '25	Sale	187.95	292	54,881	117,267	Oct 22 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 21 '25	Sale	187.95	339	63,715	152,408	Oct 22 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 21 '25	Sale	187.95	1,603	301,284	155,855	Oct 22 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 21 '25	Sale	187.95	602	113,146	70,109	Oct 22 09:05 PM
MICHAEL BROPHY	Officer	Oct 22 '25	Proposed Sale	186.88	920	171,930		Oct 22 04:36 PM
TINKERBELLE II TR U/A DTD 10/2	Officer	Oct 20 '25	Proposed Sale	190.00	10,000	1,900,000		Oct 20 04:17 PM
Sheena Jonathan	CO-FOUNDER	Oct 15 '25	Sale	175.47	3,070	538,681	236,112	Oct 17 09:05 PM
Sheena Jonathan	CO-FOUNDER	Oct 17 '25	Sale	178.91	1,500	268,361	28,032	Oct 17 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 01 '25	Sale	159.99	3,000	479,969	117,559	Oct 01 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Sep 30 '25	Sale	162.05	1,364	221,040	203,300	Oct 01 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 01 '25	Sale	160.00	14,083	2,253,233	154,072	Oct 01 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Sep 30 '25	Sale	162.05	9,109	1,476,139	168,155	Oct 01 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Sep 30 '25	Sale	162.05	2,491	403,674	69,189	Oct 01 09:35 PM
STEVEN L CHAPMAN	Officer	Oct 01 '25	Proposed Sale	160.00	14,083	2,253,233		Oct 01 04:21 PM
SOLOMON MOSHKEVICH	Officer	Oct 01 '25	Proposed Sale	159.99	3,000	479,969		Oct 01 04:13 PM
Sheena Jonathan	CO-FOUNDER	Sep 19 '25	Sale	179.47	11,000	1,974,206	28,782	Sep 22 08:05 PM
Sheena Jonathan	CO-FOUNDER	Sep 17 '25	Sale	175.94	3,070	540,148	239,182	Sep 22 08:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Sep 19 '25	Sale	180.58	25,527	4,609,599	2,320,852	Sep 19 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Sep 18 '25	Sale	180.13	14,473	2,607,069	2,346,379	Sep 19 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Sep 18 '25	Sale	180.00	10,000	1,800,000	15,000	Sep 19 09:35 PM
MATTHEW RABINOWITZ	Director	Sep 19 '25	Proposed Sale	179.86	25,527	4,591,286		Sep 19 04:27 PM
Sheena Jonathan	Director	Sep 19 '25	Proposed Sale	192.63	22,000	4,237,900		Sep 19 11:45 AM
TINKERBELLE II TR U/A DTD 10/2	Officer	Sep 18 '25	Proposed Sale	180.00	10,000	1,800,000		Sep 18 05:38 PM
MATTHEW RABINOWITZ	Director	Sep 18 '25	Proposed Sale	175.43	14,473	2,538,998		Sep 18 04:35 PM
Sheena Jonathan	Director	Sep 17 '25	Proposed Sale	175.94	9,210	1,620,445		Sep 17 10:31 AM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Sep 12 '25	Sale	170.54	5,000	852,707	25,000	Sep 16 09:03 PM
TINKERBELLE II TR U/A DTD 10/2	Officer	Sep 12 '25	Proposed Sale	170.54	5,000	852,707		Sep 12 04:33 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Sep 02 '25	Sale	166.53	5,079	845,795	158,514	Sep 05 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Sep 02 '25	Sale	166.62	3,000	499,865	120,859	Sep 05 09:05 PM
Chapman Rowan E	Director	Aug 28 '25	Sale	166.99	2,750	459,222	6,015	Sep 02 09:05 PM
STEVEN L CHAPMAN	Officer	Sep 02 '25	Proposed Sale	166.53	5,079	845,795		Sep 02 04:16 PM
SOLOMON MOSHKEVICH	Officer	Sep 02 '25	Proposed Sale	166.62	3,000	499,864		Sep 02 04:03 PM
ROWAN EMMA CHAPMAN	Director	Aug 28 '25	Proposed Sale	166.99	2,750	459,222		Aug 28 04:50 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Aug 14 '25	Sale	155.46	875	136,027	123,859	Aug 15 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Aug 14 '25	Sale	155.46	678	105,401	152,747	Aug 15 09:35 PM
Sheena Jonathan	CO-FOUNDER	Aug 08 '25	Sale	161.90	3,070	497,047	242,252	Aug 12 09:05 PM
Sheena Jonathan	CO-FOUNDER	Aug 11 '25	Sale	153.67	3,000	461,012	34,282	Aug 12 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Aug 01 '25	Sale	132.88	5,807	771,656	163,593	Aug 05 09:05 PM
Marcus Gail Boxer	Director	Aug 01 '25	Sale	133.17	2,496	332,395	5,763	Aug 05 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Aug 01 '25	Sale	132.89	3,000	398,657	123,059	Aug 05 09:05 PM
STEVEN L CHAPMAN	Officer	Aug 01 '25	Proposed Sale	132.88	5,807	771,656		Aug 01 04:22 PM
SOLOMON MOSHKEVICH	Officer	Aug 01 '25	Proposed Sale	132.89	3,000	398,657		Aug 01 04:08 PM
Marcus Gail Boxer	Director	Aug 01 '25	Proposed Sale	133.17	2,496	332,395		Aug 01 12:50 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jul 28 '25	Sale	139.81	6,092	851,712	169,400	Jul 30 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 29 '25	Sale	137.40	3,045	418,397	65,430	Jul 30 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 28 '25	Sale	139.81	2,019	282,273	68,475	Jul 30 09:45 PM
Sheena Jonathan	CO-FOUNDER	Jul 28 '25	Sale	139.81	479	66,968	245,322	Jul 30 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jul 28 '25	Sale	139.81	1,718	240,191	2,360,852	Jul 30 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jul 28 '25	Sale	139.81	2,206	308,417	126,059	Jul 30 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jul 28 '25	Sale	139.81	1,710	239,072	151,750	Jul 30 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jul 28 '25	Sale	139.81	1,994	278,778	202,164	Jul 30 09:35 PM
MICHAEL BROPHY	Officer	Jul 29 '25	Proposed Sale	138.00	3,045	420,210		Jul 29 04:25 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 22 '25	Sale	139.58	920	128,415	70,494	Jul 24 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 24 '25	Sale	139.50	755	105,320	70,494	Jul 24 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 23 '25	Sale	141.28	495	69,934	71,249	Jul 24 09:45 PM

Open in Screener

TVTX

Travere Therapeutics Inc

Nov 21 • 04:00PM ET

34.69

-0.04 -0.12 %

Healthcare • Biotechnology • USA • NASD

TVTX Travere Therapeutics Inc daily Stock Chart

Peers: BMRN RARE SRPT VYGR FOLD QURE CRSP AGIO CLLS PFE

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA PJP VHT

Index	RUT	P/E	-	EPS (ttm)	-1.08	Insider Own	1.95%	Shs Outstand	89.46M	Perf Week	0.55%
Market Cap	3.10B	Forward P/E	41.87	EPS next Y	0.83	Insider Trans	-11.43%	Shs Float	87.72M	Perf Month	23.23%
Enterprise Value	3.18B	PEG	-	EPS next Q	-0.07	Inst Own	115.88%	Short Float	12.40%	Perf Quarter	101.33%
Income	-88.54M	P/S	7.12	EPS this Y	90.13%	Inst Trans	7.96%	Short Ratio	4.87	Perf Half Y	119.00%
Sales	435.83M	P/B	42.18	EPS next Y	305.79%	ROA	-16.98%	Short Interest	10.88M	Perf YTD	99.14%
Book/sh	0.82	P/C	12.19	EPS next 5Y	-	ROE	-410.78%	52W High	36.87 -5.91%	Perf Year	99.48%
Cash/sh	2.84	P/FCF	-	EPS past 3/5Y	-10.63% -3.34%	ROIC	-22.27%	52W Low	12.91 168.71%	Perf 3Y	63.94%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	0.83% 5.87%	Gross Margin	85.08%	Volatility	4.99% 5.57%	Perf 5Y	43.88%
Dividend TTM	-	EV/Sales	7.29	EPS Y/Y TTM	77.02%	Oper. Margin	-20.59%	ATR (14)	1.80	Perf 10Y	85.31%
Dividend Ex-Date	-	Quick Ratio	2.71	Sales Y/Y TTM	114.22%	Profit Margin	-20.32%	RSI (14)	60.53	Recom	1.27
Dividend Gr. 3/5Y	- -	Current Ratio	2.75	EPS Q/Q	135.55%	SMA20	2.93%	Beta	0.89	Target Price	41.50
Payout	-	Debt/Eq	4.48	Sales Q/Q	162.11%	SMA50	20.41%	Rel Volume	0.73	Prev Close	34.73
Employees	385	LT Debt/Eq	4.40	Earnings	Oct 30 AMC	SMA200	68.08%	Avg Volume	2.23M	Price	34.69
IPO	Oct 06, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	192.20% 56.70%	Trades		Volume	1,622,039	Change	-0.12%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-25	Reiterated	Citigroup	Buy	$34 → $48
Jun-11-25	Resumed	H.C. Wainwright	Buy	$30
Jun-11-25	Reiterated	Citigroup	Buy	$35 → $32
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Oct-21-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$9 → $27
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Upgrade	Guggenheim	Neutral → Buy	$25
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Nov-20-23	Initiated	Citigroup	Neutral	$7
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $8
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform	$30
Jul-21-23	Initiated	JP Morgan	Overweight	$26
Jun-07-23	Resumed	Piper Sandler	Neutral	$22
May-22-23	Initiated	TD Cowen	Outperform	$30
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy	$37
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform	$30
Dec-14-22	Initiated	Stifel	Hold	$22